Your session is about to expire
← Back to Search
SGN-B7H4V for Advanced Cancers
Study Summary
This trial will test the safety of a new drug, SGN-B7H4V, in patients with solid tumors that have spread and are inoperable or have metastasized. The trial will also study side effects of the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition has not improved with standard treatments or I cannot tolerate them.My cancer has spread to the lining of my brain and spinal cord.My brain metastases are stable, and I haven't taken corticosteroids for them in the last 7 days.I have not had any other cancers in the last 3 years, or if I have, they are not likely to spread.I do not have severe nerve pain or damage.I have a corneal condition that needs treatment or monitoring.I have a specific type of advanced or metastatic cancer.I can provide a sample of my tumor for the study.I have previously been treated with drugs targeting B7-H4 or containing MMAE.I am fully active or can carry out light work.
- Group 1: SGN-B7H4V
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of facilities participating in this research project?
"Ten clinics are offering this clinical trial, including Sarah Cannon Research Institute at HealthONE - Denver in Denver, Mayo Clinic Florida in Jacksonville, and Community Health Network in Indianapolis. Seven other medical centres have also been tapped for patient recruitment."
What are the primary objectives of this investigation?
"This study, which will be followed for up to three years, seeks to determine the number of participants who experience dose-limiting toxicities. The secondary goals include measuring progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) within a 30-37 day period after last treatment."
How many participants are actively involved in this clinical investigation?
"Affirmative. In accordance with the data hosted on clinicaltrials.gov, this study is actively recruiting patients and has been since 1/12/2022; it was last updated in November 11th 2022. 375 individuals are needed to be enrolled from 10 different sites."
What is the known risk profile of SGN-B7H4V for patients?
"Our team at Power has gauged the safety of SGN-B7H4V as a 1, reflecting its Phase 1 status. This implies that only minimal data exists to support efficacy and security protocols."
Are there any opportunities for participation in this experiment currently available?
"Affirmative. Clinicaltrials.gov records reveal that this medical trial, launched on December 1st 2022, is presently recruiting participants. The study seeks 375 volunteers across 10 distinct clinical sites."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger